Ketan Desai
Latest Articles
Regeneron And Sanofi Lead The Way In Asthma Biologics
New Treatments For Osteoarthritis
Fiscal Cliff And The Obesity Epidemic
Will Physicians Prescribe Vivus' Qsymia?
Pfizer's Success With Its JAK Inhibitor
Results Of My Options Strategy For Vivus
Another Option Strategy For Vivus
Merck's Oral Immunotherapy For Allergic Rhino-Conjunctivitis
The Battle For The Anti-Coagulation Market
India's Iran Gambit: The Hunt For Oil
Targacept Stumbles Again
Depressing Results From Targacept's Phase III Study
Investing In A Charlie Brown Market: Options In Leveraged ETFs
One Way To Profit With Leveraged ETFs
When to Buy Biotechnology Stocks?
Earnings: What Happened to Dendreon?
Accountable Care Organizations: The Effect on Medical Care and Healthcare-Related Stocks
How Investors Should Play India's Troubling Demographics
Who Will Win the Hepatitis C Market?
Human Genome Sciences Options Prior to the FDA Decision
Will Merck Succeed Where Pfizer Did Not?
What Now for Egypt?
Abbott the Only One Left in the Osteoarthritis Game
India's Contradictory Economics
4 Lessons From a Review of Arena Articles
The Economic and Political Implications of Afghan Gold
Human Genome Sciences: Tests Raise Questions About New Lupus Drug
Eli Lilly and GlaxoSmithKline: A Tale of Two Different Pharmas
J&J Has Success with Psoriasis Treatment
On Investment and Optimism
Another Positive Indication for Amgen's Denosumab
Myriad Genetics: I Told You So